Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Cost-effectiveness of postremission intensive therapy in patients with acute leukemia.

Yu YB, Gau JP, You JY, Chern HH, Chau WK, Tzeng CH, Ho CH, Hsu HC.

Ann Oncol. 2007 Mar;18(3):529-34. Epub 2006 Dec 12.

2.

Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.

Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, Skandali A, Sakellari I, Yataganas X; Hellenic Cooperative Group.

Cancer. 2003 Apr 1;97(7):1721-31.

3.

Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China.

Huang BT, Wang Y, Du QF, Yang J, Yu J, Zeng QC, Xu N, Zhang JF, Xu LL, Luo XJ, Wei YQ, Liu XL.

Int J Hematol. 2011 Apr;93(4):474-81. doi: 10.1007/s12185-011-0804-0. Epub 2011 Mar 10.

PMID:
21387092
4.

Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia.

Shpilberg O, Haddad N, Sofer O, Raanani P, Berkowicz M, Chetrit A, Carter A, Ramot B, Tatarski I, Ben-Bassat I.

Leuk Res. 1995 Dec;19(12):893-7.

PMID:
8632657
5.

Intensive postremission chemotherapy in Taiwanese adults with acute myelogenous leukemia.

Hsu HC, Gau JP, Liu JM, Chau WK, Ho CH.

Adv Ther. 2001 Mar-Apr;18(2):67-74.

PMID:
11446270
6.

[Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].

Jin FY, Zou DH, Wang GR, Xu Y, Feng SZ, Zhao YZ, Han MZ, Yan WW, Qiu LG.

Zhonghua Xue Ye Xue Za Zhi. 2005 Nov;26(11):645-8. Chinese.

PMID:
16620547
7.

Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies.

Gaynon PS, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Steinherz PG, Sensel MG, Lee MK, Stram DO, Sather HN.

J Clin Oncol. 2001 Apr 1;19(7):1916-25.

PMID:
11283123
9.

[The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation].

Groot MT, van Agthoven M, Löwenberg B, Willemze R, Uyl-de Groot CA.

Ned Tijdschr Geneeskd. 2004 Mar 6;148(10):480-4. Dutch.

PMID:
15042895
10.

Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis.

Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A, Ligges S, Sauer T, Tschanter P, Thoennissen GB, Berning B, Kolb HJ, Reichle A, Holler E, Schwerdtfeger R, Arnold R, Scheid C, Müller-Tidow C, Woermann BJ, Hiddemann W, Berdel WE, Büchner T.

J Clin Oncol. 2014 Feb 1;32(4):288-96. doi: 10.1200/JCO.2013.50.5768. Epub 2013 Dec 23.

11.

Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience.

Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F, Molina L, Fegueux N, Pigneux A, Recher C, Rossi JF, Attal M, Sotto JJ, Maraninchi D, Reiffers J, Bardou VJ, Esterni B, Blaise D.

J Clin Oncol. 2005 Oct 20;23(30):7676-84. Epub 2005 Sep 26.

12.

Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.

Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC, Oldani E, Grassi A, Intermesoli T, Micò C, Rossi G, Fabris P, Lambertenghi-Deliliers G, Angelucci E, Barbui T, Bassan R, Rambaldi A.

Haematologica. 2007 May;92(5):612-8.

13.

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.

Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Fiere D.

J Clin Oncol. 2004 Oct 15;22(20):4075-86. Epub 2004 Sep 7.

14.

Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes.

Song KW, Barnett MJ, Gascoyne RD, Chhanabhai M, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Voss NJ, Connors JM.

Ann Oncol. 2007 Mar;18(3):535-40. Epub 2006 Dec 8.

15.

Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.

Juliusson G, Karlsson K, Lazarevic VLj, Wahlin A, Brune M, Antunovic P, Derolf A, Hägglund H, Karbach H, Lehmann S, Möllgård L, Stockelberg D, Hallböök H, Höglund M; Swedish Acute Leukemia Registry Group, the Swedish Acute Myeloid Leukemia Group, the Swedish Adult Acute Lymphoblastic Leukemia Group.

Cancer. 2011 Sep 15;117(18):4238-46. doi: 10.1002/cncr.26033. Epub 2011 Mar 8.

16.

Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.

Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S.

Haematologica. 2007 Mar;92(3):389-96.

17.

Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.

Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M.

Eur J Haematol. 2009 Aug;83(2):99-107. doi: 10.1111/j.1600-0609.2009.01256.x. Epub 2009 Apr 6.

PMID:
19385987
18.

One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.

Jourdan E, Rigal-Huguet F, Marit G, Vey N, Dastugue N, Fegueux N, Molina L, Gastaut JA, Legros L, Zerazhi H, Cailleres S, Bauduer F, Bordessoule D, Attal M, Blaise D, Pigneux A; BGMT Study Group.

Br J Haematol. 2005 May;129(3):403-10.

PMID:
15842665
19.

Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy.

Berman E, Little C, Teschendorf B, Jones M, Heller G.

Cancer. 2002 Sep 1;95(5):1064-70.

20.

Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma.

Fagnoni P, Milpied N, Limat S, Deconinck E, Nerich V, Foussard C, Colombat P, Harousseau JL, Woronoff-Lemsi MC; Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang.

Pharmacoeconomics. 2009;27(1):55-68. doi: 10.2165/00019053-200927010-00006.

PMID:
19178124
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk